Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Publication year range
1.
Exp Oncol ; 42(2): 115-119, 2020 06.
Article in English | MEDLINE | ID: mdl-32602286

ABSTRACT

AIM: To analyze the expression levels of hsa-miR-30c-5p and hsa-miR-138-1 in tumors of patients with renal cell carcinoma to determine whether they could be used as diagnostic markers. MATERIALS AND METHODS: The relative expression of hsa-miR-30c-5p and hsa-miR-138-1 was compared in the paired samples of kidney tumor tissue and conventionally normal tissue adjacent to the tumor. RESULTS: We found a significant decrease in miR-30c-5p and miR-138-1 levels in tumor tissues even in the cases of early stage cancer. In addition, miR-138-1 expression was lower in renal cell carcinoma Fuhrman grade G3 + G4 as compared to Fuhrman grade G2. However, we found no association between miR-30c-5p and miR-138-1 expression in the tumors and the major clinical and pathological characteristics of renal cell carcinoma patients. CONCLUSIONS: A significant reduction in the expression levels of hsa-miR-30c-5p and hsa-miR-138-1 in renal cell carcinoma indicates the feasibility of further studies on the probable diagnostic utility of these markers.


Subject(s)
Carcinoma, Renal Cell/genetics , Gene Expression Regulation, Neoplastic , Kidney Neoplasms/genetics , MicroRNAs/genetics , Adult , Aged , Biomarkers, Tumor/genetics , Carcinoma, Renal Cell/mortality , Carcinoma, Renal Cell/pathology , Female , Humans , Kidney Neoplasms/mortality , Kidney Neoplasms/pathology , Male , Middle Aged , Survival Rate
2.
Klin Khir ; (3): 44-8, 2014 Mar.
Article in Russian | MEDLINE | ID: mdl-25098000

ABSTRACT

Basing on analysis of results, obtained after conduction of radical prostatectomy for prostatic cancer (PC), there was stated, that an overall survival indices in terms of follow-up 3, 5 and 7 yrs have constituted (95.5 +/- 3.5), (84.1 +/- 4.7) and (71.7 +/- 6.8)%; and for the disease-free survival in the same terms--(87.05 +/- 3.20), (79.64 +/- 3.62) and (67.11 +/- 3.93)%; for the survival in terms up to 5 yrs in a localized PC--(97.18 +/- 3.27)%. In 48 (28.2%) patients a biochemical recurrence was revealed, for which the adjuvant therapy was administered. Statistically significant factors, permitting to prognosticate in patients, suffering PC stages T>T2 and biochemical recurrence, are the indices 7 points and more (in accordance to Glison scale), and initial level of a prostate speciphic antigen (PSA) 20 ng/ml and more, as well as their coincidence. Trustworthy increase of the disease recurrences rate was noted, when postoperatively a perineural invasion, positive tumoral margin and a lymph node affection were revealed. Presence of biochemical recurrence, positive surgical margin, perineural invasion and metastasis were associated with the enhanced risk of lethal outcome for the patients. Conduction of neoadjuvant hormonal therapy do not prevent a biochemical recurrence occurrence after conduction of radical prostatectomy. The tumoral process postoperative upstaging witnesses the necessity of the patients selection, owing unfavorable prognosis for administration of adjuvant hormonotherapy and radiation therapy, what impacts essentially positively a late results of surgical treatment. Application of a differentiated approach for the PC treatment permits to achieve high indices of survival in terms up to 5 yrs--(84.1 +/- 4.7)%.


Subject(s)
Neoplasm Recurrence, Local/surgery , Neoplasm Recurrence, Local/therapy , Prostatectomy , Prostatic Neoplasms/surgery , Prostatic Neoplasms/therapy , Adult , Aged , Androgen Antagonists/therapeutic use , Antineoplastic Agents, Hormonal/therapeutic use , Biomarkers, Tumor/blood , Chemotherapy, Adjuvant , Gamma Rays , Humans , Kallikreins/blood , Lymphatic Metastasis , Male , Middle Aged , Neoplasm Recurrence, Local/mortality , Neoplasm Recurrence, Local/pathology , Neoplasm Staging , Prostate-Specific Antigen/blood , Prostatic Neoplasms/mortality , Prostatic Neoplasms/pathology , Radiotherapy, Adjuvant , Survival Analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...